




RealRate

PHARMACEUTICAL 2024

Immunome Inc
Rank 97 of 309



The relative strengths and weaknesses of Immunome Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunome Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Immunome Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 285%, being 72% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	144,703
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,829
Liabilities, Non-Current	6,829
Other Assets	1,764
Other Compr. Net Income	22
Other Expenses	80,802
Other Liabilities	0
Other Net Income	2,724
Other Revenues	14,018
Property and Equipment	2,073
Research and Development	23,089
Selling, General and Administrative Expense	19,657

Output Variable	Value in 1000 USD
Assets	148,540
Liabilities	28,658
Expenses	123,548
Revenues	14,018
Stockholders Equity	119,882
Net Income	-106,806
Comprehensive Net Income	-106,795
BaseVar	158,755
ECR before LimitedLiability	174%
Economic Capital Ratio	285%